BRPI1010666A2 - peptídeos de cdc45l e vacinas incluindo dos mesmos - Google Patents

peptídeos de cdc45l e vacinas incluindo dos mesmos

Info

Publication number
BRPI1010666A2
BRPI1010666A2 BRPI1010666A BRPI1010666A BRPI1010666A2 BR PI1010666 A2 BRPI1010666 A2 BR PI1010666A2 BR PI1010666 A BRPI1010666 A BR PI1010666A BR PI1010666 A BRPI1010666 A BR PI1010666A BR PI1010666 A2 BRPI1010666 A2 BR PI1010666A2
Authority
BR
Brazil
Prior art keywords
same
vaccines including
cdc45l peptides
cdc45l
peptides
Prior art date
Application number
BRPI1010666A
Other languages
English (en)
Inventor
Tsunoda Takuya
Nishimura Yasuharu
Nakamura Yusuke
Tomita Yusuke
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BRPI1010666A2 publication Critical patent/BRPI1010666A2/pt
Publication of BRPI1010666B1 publication Critical patent/BRPI1010666B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/55—Lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI1010666-9A 2009-05-26 2010-05-25 Composição farmacêutica, métodos para indução de célula apresentadora de antígeno com indutibilidade de linfócito t citotóxico e para indução de linfócito t citotóxico, bem como usos de peptídeos BRPI1010666B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21713309P 2009-05-26 2009-05-26
US61/217,133 2009-05-26
PCT/JP2010/003488 WO2010137295A1 (en) 2009-05-26 2010-05-25 Cdc45l peptides and vaccines including the same

Publications (2)

Publication Number Publication Date
BRPI1010666A2 true BRPI1010666A2 (pt) 2017-09-12
BRPI1010666B1 BRPI1010666B1 (pt) 2021-11-23

Family

ID=43222423

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010666-9A BRPI1010666B1 (pt) 2009-05-26 2010-05-25 Composição farmacêutica, métodos para indução de célula apresentadora de antígeno com indutibilidade de linfócito t citotóxico e para indução de linfócito t citotóxico, bem como usos de peptídeos

Country Status (16)

Country Link
US (1) US8586547B2 (pt)
EP (4) EP3208334B1 (pt)
JP (1) JP5903697B2 (pt)
KR (1) KR101765452B1 (pt)
CN (3) CN103694315B (pt)
AU (1) AU2010253356B2 (pt)
BR (1) BRPI1010666B1 (pt)
CA (3) CA3011607C (pt)
DK (3) DK3556857T3 (pt)
ES (3) ES2746334T3 (pt)
IL (1) IL216211A (pt)
MX (1) MX2011012619A (pt)
RU (1) RU2562160C2 (pt)
SG (1) SG176058A1 (pt)
TW (1) TWI507204B (pt)
WO (1) WO2010137295A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2771350B1 (en) * 2011-10-28 2018-01-10 OncoTherapy Science, Inc. Topk peptides and vaccines including the same
EP3202783A1 (en) * 2016-02-02 2017-08-09 Ecole Polytechnique Federale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
DK3573600T3 (da) 2017-01-25 2022-05-09 Ose Immunotherapeutics Fremgangsmåde til fremstilling af en stabil emulsion til peptidlevering
JP7317023B2 (ja) 2017-09-20 2023-07-28 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 新規抗ｈｌａ－ａ２抗体、およびその使用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
DE69635895D1 (de) 1995-08-03 2006-05-04 Rijksuniversiteit Te Leiden Le Antigen presentierende bläschen, die von zellen ableiten
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
US20020132253A1 (en) * 1997-06-16 2002-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
CA2331761A1 (en) 1998-06-25 1999-12-29 Sumitomo Pharmaceuticals Co., Ltd. Tumor antigen peptides originating in cyclophilin b
EP1377609B1 (en) 2001-03-14 2015-06-24 Dako Denmark A/S Mhc molecule constructs and their uses for diagnosis and therapy
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
US7514084B2 (en) * 2002-09-12 2009-04-07 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
JP4370409B2 (ja) 2005-06-22 2009-11-25 国立大学法人東北大学 がんの予後予測方法
WO2007013665A2 (en) 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
EP2295602B1 (en) * 2005-07-27 2012-07-11 Oncotherapy Science, Inc. Method of prognosing cancers
WO2007032255A1 (ja) 2005-09-13 2007-03-22 Mie University Ｔ細胞レセプター及び該レセプターをコードする核酸
ATE509096T1 (de) 2006-06-16 2011-05-15 Onco Therapy Science Inc Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält
US8470534B2 (en) 2006-12-01 2013-06-25 Erik S. Knudsen Methods of predicting resistance or sensitivity to therapies for cancer
TWI441648B (zh) * 2007-01-03 2014-06-21 Oncotherapy Science Inc Ｆｏｘｐ３胜肽疫苗

Also Published As

Publication number Publication date
CN105153279A (zh) 2015-12-16
CA2762934A1 (en) 2010-12-02
BRPI1010666B1 (pt) 2021-11-23
IL216211A0 (en) 2012-01-31
EP3868778A2 (en) 2021-08-25
JP2012527867A (ja) 2012-11-12
EP2435567A1 (en) 2012-04-04
AU2010253356B2 (en) 2015-09-24
CA2762934C (en) 2018-09-04
ES2631952T3 (es) 2017-09-06
CA3011607C (en) 2022-09-13
IL216211A (en) 2016-06-30
US20120164163A1 (en) 2012-06-28
KR20120018203A (ko) 2012-02-29
EP3868778A3 (en) 2021-11-03
RU2562160C2 (ru) 2015-09-10
CN102459589B (zh) 2013-12-25
AU2010253356A1 (en) 2011-12-01
CN105153279B (zh) 2018-09-11
EP3556857A2 (en) 2019-10-23
EP3208334A3 (en) 2017-10-18
JP5903697B2 (ja) 2016-04-20
RU2011152975A (ru) 2013-07-10
US8586547B2 (en) 2013-11-19
DK3556857T3 (da) 2021-07-12
ES2746334T3 (es) 2020-03-05
SG176058A1 (en) 2011-12-29
KR101765452B1 (ko) 2017-08-07
WO2010137295A1 (en) 2010-12-02
EP3556857A3 (en) 2019-12-04
CA3167451A1 (en) 2010-12-02
CN103694315B (zh) 2015-07-29
CA3011607A1 (en) 2010-12-02
EP3556857B1 (en) 2021-05-05
ES2875950T3 (es) 2021-11-11
EP2435567A4 (en) 2013-03-13
MX2011012619A (es) 2012-01-30
EP3208334A2 (en) 2017-08-23
TWI507204B (zh) 2015-11-11
DK3208334T3 (da) 2019-09-30
DK2435567T3 (en) 2017-07-24
TW201106962A (en) 2011-03-01
CN102459589A (zh) 2012-05-16
EP3208334B1 (en) 2019-07-03
EP2435567B1 (en) 2017-05-03
CN103694315A (zh) 2014-04-02

Similar Documents

Publication Publication Date Title
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BR112012004731A2 (pt) peptídeos derivados de wnt10 e uso dos mesmos
BR112012006501A2 (pt) polipeptídios e usos dos mesmos
DK2552434T3 (da) Peptider og anvendelse deraf
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
BR112013004175A2 (pt) aparelho e conjunto atuado piezoelétrico
BR112012001260A2 (pt) conjugados de epsilon-polilisina e o emprego dos mesmos
BR112015001628A2 (pt) polipeptídeos de fator x modificados e uso dos mesmos
BRPI0914782A2 (pt) peptídeos de epítopos de cdca1 e vacinas contendo os mesmos
BR112012002072A2 (pt) polipeptídeos de fator ix modificados e usos dos mesmos
BR112012028157A2 (pt) dispositivo para colheita de azeitonas e similares
BRPI1008887A2 (pt) peptídeos de foxm1 e vacinas contendo os mesmo
BR112012003844A2 (pt) vacinas de pttv e diagnóstico
BRPI1009301A2 (pt) peptídeos neil 3 e vacinas incluindo os mesmos
BRPI0917391A2 (pt) peptídeo de epítodo de hig2 e urlc10 e vacinas contendo o mesmo
BRPI1010666A2 (pt) peptídeos de cdc45l e vacinas incluindo dos mesmos
BRPI1013938A2 (pt) "peptídeos ttk e vacinas incluindo os mesmos"
BRPI1011314A2 (pt) conjugados de albumina-peptídeo amilóide e usos dos mesmos
BR112013013158A2 (pt) peptídeos de tomm34 e vacinas incluindo os mesmos
BRPI0919766A2 (pt) peptídeo de epítopo de rab6kifl/kif20a e vacinas contendo o mesmo
BRPI1012312A2 (pt) peptídeos vangl1 e vacinas incluindo os mesmos
BRPI0923402A2 (pt) Peptídeos c10rf59 e vacinas incluindo os mesmos.
BRPI1013384A2 (pt) peptídeos c6orf167 e vacinas incluindo os mesmos
ZA201207342B (en) Ect2 peptides and vaccines including the same
BRPI0923938A2 (pt) novos peptideos e uso dos mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/05/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2776 DE 19-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.